October is Breast Cancer Awareness Month, and fittingly, University of New Mexico Comprehensive Cancer Center biologist Curt ...

It may surprise many to hear that some of today’s most advanced treatments, such as cell therapies for cancer, diabetes, and autoimmunity, depend on flow cytometry — a 50-year old technology.

Despite the dazzle of its spectral capabilities, flow cytometry is helping users focus on their research, clinical, and diagnostic applications.

SAN ANTONIO, October 16, 2024--(BUSINESS WIRE)--bioAffinity Technologies’ (Nasdaq: BIAF; BIAFW) Vice President of Diagnostics, Jennifer Rebeles, Ph.D., was part of a panel of worldwide experts ...

Research uncovers how P-stalk ribosomes regulate cytokine responses, driving immune evasion in tumors across multiple cancer types. It offers new insights into post-translational mechanisms ...

We performed integration-site analysis, genetic studies, flow cytometry, and morphologic studies ... features of seven cases of hematologic cancer (as of April 25, 2024) in patients who received ...

High Content Screening MarketThe global high content screening (HCS) market is set to experience impressive growth, with its market value expected to soar beyond USD 3 billion by 2033, up from over ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced ...

“Our CyPath® Lung noninvasive test for the early detection of lung cancer is a novel test that uses sputum, a unique sample type that is not typically used in clinical flow cytometry assays ...

(2024-10-16 | NDAQ:BIAF) bioAffinity's CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines ...